Summary:
A longitudinal neuroimaging investigation published in Neurology, the medical journal of the American Academy of Neurology, demonstrates that longer lifetime estrogen exposure and hormonal therapy use are strongly tied to preserved cerebrovascular health in older women.
Researchers from the Karolinska Institutet tracked 352 cognitively healthy 70-year-old women over five years using brain MRI scans. They found that a longer reproductive lifespan was associated with an 8% reduction in cerebral small vessel disease markers, while menopausal hormone therapy cut high vascular burden risk by 59%. Women who combined past oral contraceptive use with later menopausal hormone therapy exhibited the most resilient white matter integrity and lowest vessel damage.
Key Facts:
- Protection Against Small Vessel Disease: Each additional year of reproductive lifespan (the interval between menarche and menopause) was tied to an 8% lower likelihood of exhibiting multiple MRI signs of cerebral small vessel disease at age 70 to 75.
- 59% Reduced Vascular Disease Burden: Women who had used or were currently taking menopausal hormone therapy (MHT) experienced a 59% lower risk of high small vessel disease burden, displaying significantly fewer cerebral microbleeds and perivascular space enlargements.
- Cumulative Hormonal Benefit: Participants who utilized oral contraceptives during reproductive years and subsequently received menopausal hormone therapy showed the highest white matter microstructural integrity and lowest vascular damage compared to non-users.
Source: American Academy of Neurology / Karolinska Institutet
Cerebral small vessel disease (CSVD) represents a major vascular contributor to cognitive decline, gait impairment, subcortical strokes, and vascular dementia in aging populations. Characterized by covert microstructural pathology within penetrating arterioles and capillaries, CSVD damages white matter connectivity long before clinical neurodegeneration becomes apparent.
Epidemiological data have consistently documented that women experience disproportionately higher rates of Alzheimer’s disease and age-related dementias compared to men. While female longevity accounts for part of this gap, neuroscientists increasingly look to the lifelong biological transitions of female endocrine aging, specifically the withdrawal of 17β-estradiol during the menopausal transition, as a primary vulnerability factor.
Estrogen exerts potent vasodilatory, anti-inflammatory, and neuroprotective influences on endothelial cells and the blood-brain barrier. However, how cumulative lifetime exposure to endogenous and exogenous estrogens influences late-life cerebrovascular architecture has remained understudied.
Now, a five-year longitudinal neuroimaging study published in Neurology by researchers at the Karolinska Institutet in Stockholm, Sweden, indicates that sustained estrogen exposure across adulthood helps preserve the brain’s microvasculature well into older age.
Tracking 352 Women Across Five Years of Brain Aging
Led by Dr. Anna Marseglia, PhD, of the Department of Neurobiology, Care Sciences and Society at the Karolinska Institutet, the research team analyzed a well-characterized cohort of 352 women who entered the study at age 70 with intact cognitive faculties.
The investigators cataloged lifetime reproductive timelines, defining natural reproductive lifespan as the number of years between menarche (first menstrual period) and natural menopause or bilateral oophorectomy (surgical ovarian removal). The average reproductive duration among participants was 37 years.
Exogenous hormone histories were systematically audited:
- Oral Contraceptive Use: 73% of participants reported previous use of birth control pills during reproductive years.
- Menopausal Hormone Therapy (MHT): 61% of participants had taken or were actively taking hormone therapy to manage menopausal symptoms.
Participants underwent comprehensive 3T magnetic resonance imaging (MRI) at age 70, followed by repeat scanning five years later at age 75. Neuroradiologists scored four cardinal neuroimaging markers of cerebral small vessel disease:
- White Matter Hyperintensities (WMHs): Confluent lesions reflecting ischemic myelin rarefaction.
- Cerebral Microbleeds: Tiny focal perivascular hemosiderin deposits.
- Lacunes: Small, fluid-filled subcortical ischemic cavities.
- Perivascular Spaces (PVS): Pathological enlargement of interstitial fluid-drainage conduits surrounding penetrating vessels.
Each scan was assigned a cumulative CSVD burden score ranging from zero to four based on the presence of these vascular features.
Significant Reductions in Vascular Pathology
After multivariable adjustments controlling for educational attainment, parity (number of pregnancies), and cumulative breastfeeding duration, statistical modeling confirmed that a longer natural reproductive lifespan provided quantifiable protection: each additional reproductive year was associated with an 8% reduction in the odds of presenting with two or more severe markers of cerebral small vessel disease.
The protective association was even more pronounced among recipients of menopausal hormone therapy. Controlling for cardiovascular confounders, including chronic hypertension, cardiac disease, and socioeconomic background, women with an MHT history exhibited a 59% lower risk of presenting with high small vessel disease burden. These women had substantially fewer cerebral microbleeds and preserved perivascular space architecture.
Furthermore, advanced diffusion-weighted imaging confirmed that both oral contraceptive use and MHT correlated with superior white matter microstructural integrity, indicating preserved axonal insulation and reduced tissue breakdown.
“Women are affected by Alzheimer’s disease more often than men. This may be related, in part, to fluctuations in estrogen levels throughout life,” said Dr. Marseglia. “Estrogen is known to have protective effects on both neuronal cells and blood vessels in the brain. However, its potential role in women’s cerebrovascular health in later life has been largely understudied. Our study found that factors associated with longer estrogen exposure were associated with fewer signs of cerebral small vessel disease and better brain health in older age.”
The Cumulative Impact of Dual Hormonal Support
A key finding emerged when examining the sequence of exogenous hormone exposure. Participants who had taken oral contraceptives in their younger years and subsequently received menopausal hormone therapy during midlife displayed the lowest incidence of small vessel damage and the healthiest white matter integrity across the entire cohort.
“What was particularly striking was that the most favorable vascular brain health was observed among women who had used oral contraceptives during their reproductive years and later received menopausal hormone therapy,” Dr. Marseglia noted. “This suggests that hormonal factors acting across different stages of a woman’s life may have cumulative associations with cerebrovascular health in older age. While these findings do not establish cause and effect, they underscore the importance of considering women’s reproductive and hormonal history when studying brain aging and dementia risk not only in relation to Alzheimer’s disease but also to vascular disease.”
Methodological Considerations and Future Horizons
The authors note several epidemiological constraints. Retrospective self-reporting of menarche, oral contraceptive regimens, and MHT duration introduces potential recall bias, and serum estrogen concentrations were not tracked prospectively across the lifespan. Additionally, because the study focused exclusively on cisgender female participants, the biological patterns may not generalize across all populations.
Nevertheless, by demonstrating that sustained estrogen exposure correlates with reduced structural vascular injury, the study reframes women’s reproductive history not simply as an endocrine narrative, but as a critical determinant of lifelong cerebrovascular health and vascular dementia risk.
Questions and Answers
How does a longer reproductive lifespan affect brain health in older women?
A longer reproductive lifespan, the time between menarche and menopause, is associated with an 8% lower risk of developing moderate to severe cerebral small vessel disease markers by age 70 to 75, suggesting that longer exposure to endogenous estrogen supports vascular health in the brain.
What specific brain changes were reduced by menopausal hormone therapy?
Women using or with a history of menopausal hormone therapy had a 59% lower risk of high small vessel disease burden. On MRI scans, these women exhibited significantly fewer microbleeds, reduced perivascular space enlargement, and superior white matter microstructural integrity.
Did using birth control pills in youth make a difference in later life?
Yes. Women who used birth control pills during their reproductive years and later used menopausal hormone therapy displayed the most favorable cerebrovascular profiles, with the lowest overall vessel disease burden and the healthiest white matter compared to non-users.
Funding: The study was supported by: the Swedish Research Council; the Swedish Research Council for Health, Working Life and Welfare; the Center for Innovative Medicine; the Swedish Dementia Foundation; the Swedish Alzheimer’s Foundation; and the Gamla Tjännarinor Foundation.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper will be reviewed in full upon release.
- Additional context added by our staff.
About this neuroscience and brain aging Research:
- Media Contact: Natalie Conrad
- Source: AAN
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: The findings will appear in Neurology
